.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,883,111

« Back to Dashboard

Details for Patent: 5,883,111

Title: Heterocyclic compounds and their use as angiotensin antagonists
Abstract:
Inventor(s): Naka; Takehiko (Kobe, JP), Inada; Yoshiyuki (Kawanishi, JP)
Assignee: Takeda Chemical Industries, Ltd. (Osaka, JP)
Filing Date:Jul 22, 1996
Application Number:08/685,907
Claims:1. A compound of the formula: ##STR75## wherein R.sup.1 is an optionally substituted hydrocarbon residue which is optionally bonded through a heteroatom; R.sup.2 is selected from the group consisting of ##STR76## wherein g is i) --CH.sub.2 --, ii) --NR.sup.9 --, wherein R.sup.9 is hydrogen or lower (C.sub.1-4) alkyl, iii) --O-- or iv) --S(O).sub.m -- wherein m is an integer of 0 to 2, and >.dbd.Z and >.dbd.Z' and >.dbd.Z" are independently a carbonyl group, a thiocarbonyl group, or an optionally oxidized sulfur atom; X is a direct bond or a spacer having an atomic length of two or less between the ring Y and the ring W; W and Y are independently an optionally substituted aromatic hydrocarbon residue optionally containing a hetero atom or an optionally substituted heterocyclic residue; n is an integer of 1 or 2; and the group of the formula: ##STR77## is a group selected from the class consisting of ##STR78## wherein h is >CH.sub.2, >C.dbd.O, >C.dbd.S, >S--(O).sub.m, wherein m is an integer of 0-2, --NR.sup.9 --, wherein R.sup.9 is hydrogen or lower (C.sub.1-4) alkyl) or --O--; and the group of the formula: ##STR79## may be optionally substituted, in addition to the group R.sup.1 and, when (a) is an optionally substituted carbon atom, R.sup.1 and (a) may optionally be bonded to each other to form a ring group of a formula selected from the group consisting of ##STR80## wherein R.sup.1a stands for an optionally substituted hydrocarbon residue and h" stands for --O-- or --S--" or a salt thereof.

2. A compound according to claim 1, wherein R.sup.1, is alkyl, alkenyl, alkynyl or cycloalkyl which may be bound through a group of the formula: --N(R.sup.9)--, wherein R.sup.9 is hydrogen or lower (C.sub.1-4) alkyl, --O-- or --S(O).sub.m --, wherein m is an integer of 0 to 2, and wherein R.sup.1 may be substituted with hydroxy, optionally substituted amino, halogen, lower (C.sub.1-4) alkoxy or lower (C.sub.1-4) alkylthio.

3. A compound according to claim 1, wherein R.sup.1 is aryl or aralkyl which may be bound through a group of the formula: --N(R.sup.9)--, wherein R.sup.9 is hydrogen or lower (C.sub.1-4) alkyl, --O-- or --S(O).sub.m --, wherein m is an integer of 0 to 2, and wherein R.sup.1 may be substituted with halogen, nitro, optionally substituted amino, lower (C.sub.1-4) alkoxy, lower (C.sub.1-4) alkylthio or lower (C.sub.1-4) alkyl.

4. A compound according to claim 1, wherein R.sup.1 is lower (C.sub.1-8) alkyl or lower (C.sub.2-8) alkenyl which may be bound through a group of the formula: --N(R.sup.9)--, wherein R.sup.9 is hydrogen or lower (C.sub.1-4) alkyl, --O-- or --S(O).sub.m --, wherein m is an integer of 0 to 2, and wherein R.sup.1 may be substituted with hydroxy, amino, N-lower (C.sub.1-4) alkylamino, N,N-dilower (C.sub.1-4) alkyamino, halogen, lower (C.sub.1-4) alkoxy or lower (C.sub.1-4) alkylthio.

5. A compound according to claim 1, wherein R.sup.1 is lower (C.sub.1-5) alkyl or lower (C.sub.2-5) alkenyl which may be bound through a group of the formula: --N(R.sup.9)--, wherein R.sup.9 is hydrogen or lower (C.sub.1-4) alkyl, --O-- or --S(O).sub.m --, wherein m is an integer of 0 to 2, and wherein R.sup.1 may be substituted with hydroxy, amino, halogen or lower (C.sub.1-4) alkoxy.

6. A compound according to claim 1, wherein R.sup.2 is a group of the formula: ##STR81## wherein i is --O-- or --S-- and j is carbonyl group, thiocarbonyl group or an optionally oxidized sulfur atom.

7. A compound according to claim 1, wherein R.sup.2 is 2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl group.

8. A compound according to claim 1, wherein R.sup.2 is 2,5-dihydro-5-oxo-1,2,4-thiadiazol-3-yl group.

9. A compound according to claim 1, wherein R.sup.2 is 2,5-dihydro-5-thioxo-1,2,4-oxadiazol-3-yl group.

10. A compound according to claim 1, wherein W and Y are independently phenyl, pyridyl, pyrimidinyl, pyrazinyl, thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isooxazolyl, benzofuranyl, isobenzofuranyl, indolizinyl, isoindolyl, 3-indolyl, indolyl, 1H-indazolyl, purinyl, 4H-quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl or pterdinyl, which may be substituted with halogen, nitro, cyano, lower (C.sub.1-4) alkoxy or optionally substituted amino.

11. A compound according to claim 1, wherein W is a phenylene group.

12. A compound according to claim 1, wherein Y is a phenyl group.

13. A compound according to claim 1, wherein X is a direct bond, lower (C.sub.1-4) alkylene, --CO--, --O--, --S--, --NH--, --CO--NH--, --O--CH.sub.2 --, --S--CH.sub.2 -- or --CH.dbd.CH--.

14. A compound according to claim 1, wherein X is a direct bond.

15. A compound according to claim 1, wherein n is an integer of 1.

16. A compound according to claim 1, wherein the group of the formula: ##STR82## in which R is the group of the formula: ##STR83## is selected from the group consisting of ##STR84## wherein R.sup.3 is a group capable of forming an anion.

17. A compound according to claim 16, wherein R.sup.3 is an optionally esterified or amidated carboxyl, tetrazolyl, trifluoromethanesulfonic amide, phosphoric acid or sulfonic acid, which may be protected with an optionally substituted lower alkyl or acyl.

18. A compound according to claim 17, wherein R.sup.3 is a group of the formula: --CO--D, wherein D is hydroxy, an optionally substituted amino or an optionally substituted alkoxy.

19. A compound according to claim 18, wherein the optionally substituted alkoxy is lower (C.sub.1-6) alkoxy whose alkyl moiety may be substituted by hydroxy, optionally substituted amino, halogen, lower (C.sub.1-6) alkoxy, lower (C.sub.1-6) alkylthio or optionally substituted dioxolenyl, or a group of the formula: --O--CH(R.sup.4)--OCOR.sup.5 wherein R.sup.4 is hydrogen, lower (C.sub.1-6) alkyl, lower (C.sub.2-6) alkenyl or lower (C.sub.3-8) cycloalkyl; and R.sup.5 is lower (C.sub.1-6) alkyl, lower (C.sub.2-6) alkenyl, lower (C.sub.3-8) cycloalkyl, lower (C.sub.1-3) alkyl substituted with lower (C.sub.3-8) cycloalkyl or aryl, lower (C.sub.2-3) alkenyl optionally substituted with lower (C.sub.3-8) cycloalkyl or aryl, aryl, lower (C.sub.1-6) alkoxy, lower (C.sub.2-8) alkenyloxy, lower (C.sub.3-8) cycloalkyloxy, lower (C.sub.1-3) alkoxy substituted with lower (C.sub.3-8) cycloalkyl or aryl, lower (C.sub.2-3) alkenyloxy substituted with lower (C.sub.3-8) cycloalkyl or aryl, or aryloxy.

20. A compound according to claim 18, wherein R.sup.3 is an optionally esterified carboxy.

21. A pharmaceutical composition for antagonizing angiotensin II which comprises a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable carrier, excipient or diluent.

22. A method for antagonizing angiotensin II in a mammal which comprises administering to said mammal, a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

23. A compound according to claim 1, which is ethyl 2-ethyl-4,7-dihydro-7((2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl -4-yl)methyl)-4-oxothieno(2,3-b)pyridine-5-carboxylate.

24. A compound according to claim 1, which is 3-((2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl)-2-pro pyl-4(3H)-quinazolinone.

25. A compound according to claim 1, which is 5-butyl-3-ethyoxycarbonyl-1-((2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)b iphenyl-4-yl)methylpyrazole.

26. A compound according to claim 1, which is 2-butyl-4-chloro-1-(2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4- yl]methyl)imidazole-5-carboxylic acid.

27. A compound according to claim 1, which is 1-((2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl)-6-pro poxy-3-propyluracil.

28. A compound according to claim 1, wherein the group of the formula: ##STR85## may be optionally substituted, in addition to R.sup.1, with a substituent selected from the group consisting of halogen, nitro, cyano, an optionally substituted amino group, groups represented by the formula --U--R.sup.6, wherein U stands for a bond, --O--, --S-- or --CO--, and R.sup.6 stands for hydrogen or an optionally substituted lower alkyl group, groups represented by the formula --(CH.sub.2).sub.1 --CO-- D', wherein D' stands for hydrogen, hydroxyl group, optionally substituted amino, or optionally substituted alkoxy or groups represented by the formula --OCH(R.sup.7)OCOR.sup.8, wherein R.sup.7 stands for hydrogen, 1-6C straight-chain or branched lower alkyl group or a 5-7C cycloalkyl group, and R.sup.8 stands for a 1-6C straight-chain or branched lower alkyl group, a 2-8C lower alkenyl group, a 5-7C cycloalkyl group, a 1-3C lower alkyl group substituted with a 5-7 cycloalkyl group or an aryl group, a 2-3C lower alkenyl group substituted with 5-7C cycloalkyl or an aryl group, an optionally substituted aryl group, a 1-6C straight-chain or branched lower alkoxy group, a 2-8C straight-chain or branched lower alkenyloxy group, a 5-7C cycloalkyloxy group, a 1-3C lower alkoxy group substituted with 5-7C cycloalkyl or an aryl group, a 2-3C alkenyloxy group substituted with 5-7C cycloalkyl or an optionally substituted aryl group, or an aryloxy group, and 1 denotes 0 or 1; and tetrazolyl, trifluoromethanesulfonic acid amide, phosphoric acid or sulfonic acid, each optionally protected with alkyl or acyl,

wherein one or more of these substituents may optionally be substituted simultaneously on optional positions of the ring.

29. A compound according to claim 1, wherein R.sup.1 and (a) are not bonded to each other to form said ring group.

30. A compound of the formula: ##STR86## wherein the group of the formula: ##STR87## is a group selected from the class consisting of ##STR88## which may be optionally substituted, in addition to the group R.sup.1 and R.sup.3,

R.sup.2 is a group of the formula: ##STR89## wherein i is --O-- or --S-- and j is >C.dbd.O, >C.dbd.S or >S(O)m, wherein m is an integer of 0 to 2, or R.sup.2 is hydroxyiminocarboxamide;

R.sup.1 is lower (C.sub.1-5) alkyl which may be bound through --O--, --NH-- or --S-- and which may be substituted with hydroxy, amino, N-lower (C.sub.1-4) alkylamino, N,N-di-lower (C.sub.1-4) alkylamino, halogen, lower (C.sub.1-4) alkoxy or lower (C.sub.1-4) alkylthio; and

R.sup.3 is a group of the formula: --CO--D" wherein D" is hydroxy, amino, N-lower (C.sub.1-4) alkylamino, N,N-di-lower (C.sub.1-4) alkylamino or lower (C.sub.1-4) alkoxy whose alkyl moiety may be substituted by hydroxy, amino, halogen, lower (C.sub.2-6) alkanoyloxy, 1-lower (C.sub.1-6) alkoxycarbonyloxy or lower (C.sub.1-4) alkoxy, or tetrazolyl optionally protected with lower (C.sub.1-4) alkyl or acyl; or a pharmaceutically acceptable salt thereof.

31. A compound according to claim 30, wherein R.sup.2 is hydroxyiminocarboxamide.

32. A compound according to claim 30, wherein R.sup.2 is other than said hydroxyiminocarboxamide.

33. A compound according to claim 30, wherein R.sup.1 is (C.sub.2-4) alkyl which may be bound through --O--, --NH-- or --S--.

34. A compound according to claim 30, wherein R.sup.3 is an optionally esterified carboxy.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc